CRISPR Therapeutics grants CEO 57,500 stock options

The chief executive officer's option begins monthly vesting in November 2026, while the restricted stock units vest annually from 2027 through 2030.

Rhea-AI Filing Summary

CRISPR Therapeutics AG Chief Executive Officer Samarth Kulkarni was granted a stock option covering 57,500 Common Shares and restricted stock units covering 28,750 Common Shares on October 26, 2026. The option has an exercise price of $49.01 per share, vests in 48 equal monthly installments beginning November 26, 2026, and expires October 26, 2036. Each restricted stock unit represents a contingent right to receive one Common Share; one quarter vests on each of October 26, 2027, 2028, 2029, and 2030.

Insider Trade Summary

Grant/Award: 86,250 shares

Grant/Award 2 txns

Insider Kulkarni Samarth

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	57,500	$0.00	$0.00
Grant/Award	Restricted Stock Units F2, F3	28,750	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 57,500 contracts (Direct); Restricted Stock Units — 28,750 contracts (Direct)

Footnotes (3)

1. F1. This option was granted on October 26, 2026 with respect to 57,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.
2. F2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
3. F3. This restricted stock unit award was granted on October 26, 2026 with respect to 28,750 Common Shares, with (i) one quarter of the shares vesting on October 26, 2027, (ii) one quarter of the shares vesting on October 26, 2028, (iii) one quarter of the shares vesting on October 26, 2029, and (iv) one quarter of the shares vesting on October 26, 2030.

Key Figures

Stock option award: 57,500 Common Shares Option exercise price: $49.01 per share Option vesting schedule: 48 equal monthly installments +4 more

7 metrics

Stock option award 57,500 Common Shares Granted October 26, 2026

Option exercise price $49.01 per share Stock option grant

Option vesting schedule 48 equal monthly installments First vesting date November 26, 2026

Option expiration October 26, 2036 Stock option

Restricted stock unit award 28,750 Common Shares Granted October 26, 2026

Shares per restricted stock unit 1 Common Share Each unit represents a contingent right to receive one share

Restricted stock unit vesting One quarter on each of October 26, 2027; October 26, 2028; October 26, 2029; and October 26, 2030 Restricted stock unit award

Key Terms

Stock Option (Right to Buy), restricted stock unit, contingent right, equal monthly installments

4 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

restricted stock unit financial

"Each restricted stock unit represents a contingent right"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

contingent right financial

"represents a contingent right to receive one share"

equal monthly installments financial

"vest in 48 equal monthly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did CRSP CEO Samarth Kulkarni receive?

Samarth Kulkarni, CRISPR Therapeutics AG’s Chief Executive Officer, was granted an option covering 57,500 Common Shares and restricted stock units covering 28,750 Common Shares on October 26, 2026. The option’s exercise price is $49.01 per share.

When do Samarth Kulkarni’s CRSP restricted stock units vest?

The 28,750 restricted stock units vest in four equal installments, with one quarter vesting on October 26, 2027, October 26, 2028, October 26, 2029, and October 26, 2030. Each unit represents a contingent right to receive one Common Share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/28/2026 - 05:39 PM EDT Accepted by SEC EDGAR 10/28/2026 - 05:38 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kulkarni Samarth

(Last) (First) (Middle)

C/O CRISPR THERAPEUTICS

105 WEST FIRST STREET

(Street)

BOSTON MASSACHUSETTS 02127

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CRISPR Therapeutics AG [ CRSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$49.01	10/26/2026		A		57,500		(1)	10/26/2036	Common Shares	57,500	$0	57,500	D
Restricted Stock Units	(2)	10/26/2026		A		28,750		(3)	(3)	Common Shares	28,750	$0	28,750	D

Explanation of Responses:

1. This option was granted on October 26, 2026 with respect to 57,500 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 26, 2026.

2. Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.

3. This restricted stock unit award was granted on October 26, 2026 with respect to 28,750 Common Shares, with (i) one quarter of the shares vesting on October 26, 2027, (ii) one quarter of the shares vesting on October 26, 2028, (iii) one quarter of the shares vesting on October 26, 2029, and (iv) one quarter of the shares vesting on October 26, 2030.

	Elizabeth Ryland Waldinger, attorney-in-fact	10/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)